CA2558640A1 - Procedes et compositions s'utilisant dans le trans-epissage d'arn induit par complexe d'epissage - Google Patents

Procedes et compositions s'utilisant dans le trans-epissage d'arn induit par complexe d'epissage Download PDF

Info

Publication number: CA2558640A1
Authority: CA; Canada
Prior art keywords: nucleic acid; acid molecule; cell; mrna; target
Prior art date: 2001-01-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002558640A

Other languages

English (en)

Inventor

Lloyd G. Mitchell

Mariano A. Garcia-Blanco

Carl C. Baker

Madaiah Puttaraju

Gary S. Mansfield

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

VirxSys Corp

US Department of Health and Human Services

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-01-08

Filing date

2002-01-08

Publication date

2002-07-11

2001-01-08 Priority claimed from US09/756,096 external-priority patent/US20030077754A1/en

2001-01-08 Priority claimed from US09/756,095 external-priority patent/US20020115207A1/en

2001-01-08 Priority claimed from US09/756,097 external-priority patent/US20060088938A1/en

2001-04-20 Priority claimed from US09/838,858 external-priority patent/US20030148937A1/en

2001-08-29 Priority claimed from US09/941,492 external-priority patent/US20030027250A1/en

2002-01-08 Application filed by Individual filed Critical Individual

2002-01-08 Priority claimed from CA002434118A external-priority patent/CA2434118A1/fr

2002-07-11 Publication of CA2558640A1 publication Critical patent/CA2558640A1/fr

Status Abandoned legal-status Critical Current

Links

230000001404 mediated effect Effects 0.000 title claims description 31
210000001324 spliceosome Anatomy 0.000 title description 19
108020004999 messenger RNA Proteins 0.000 claims abstract description 274
108090000623 proteins and genes Proteins 0.000 claims abstract description 184
238000000034 method Methods 0.000 claims abstract description 85
102000004169 proteins and genes Human genes 0.000 claims abstract description 83
230000014509 gene expression Effects 0.000 claims abstract description 42
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 42
108091092236 Chimeric RNA Proteins 0.000 claims abstract description 30
230000027455 binding Effects 0.000 claims description 260
108020005067 RNA Splice Sites Proteins 0.000 claims description 150
102000039446 nucleic acids Human genes 0.000 claims description 129
108020004707 nucleic acids Proteins 0.000 claims description 129
150000007523 nucleic acids Chemical class 0.000 claims description 129
239000002773 nucleotide Substances 0.000 claims description 88
125000003729 nucleotide group Chemical group 0.000 claims description 85
125000006850 spacer group Chemical group 0.000 claims description 54
241001631646 Papillomaviridae Species 0.000 claims description 51
239000013598 vector Substances 0.000 claims description 43
230000000295 complement effect Effects 0.000 claims description 32
230000015572 biosynthetic process Effects 0.000 claims description 21
239000000203 mixture Substances 0.000 claims description 21
102000004196 processed proteins & peptides Human genes 0.000 claims description 20
230000003612 virological effect Effects 0.000 claims description 20
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 19
229920001184 polypeptide Polymers 0.000 claims description 18
239000013604 expression vector Substances 0.000 claims description 17
241000701806 Human papillomavirus Species 0.000 claims description 16
239000013603 viral vector Substances 0.000 claims description 9
230000003993 interaction Effects 0.000 claims description 8
231100000590 oncogenic Toxicity 0.000 claims description 6
230000002246 oncogenic effect Effects 0.000 claims description 6
230000002401 inhibitory effect Effects 0.000 claims description 5
241000700605 Viruses Species 0.000 claims description 4
208000019065 cervical carcinoma Diseases 0.000 claims description 2
238000006243 chemical reaction Methods 0.000 abstract description 95
238000004519 manufacturing process Methods 0.000 abstract description 24
239000003053 toxin Substances 0.000 abstract description 20
231100000765 toxin Toxicity 0.000 abstract description 20
238000001727 in vivo Methods 0.000 abstract description 17
238000001261 affinity purification Methods 0.000 abstract description 8
230000001225 therapeutic effect Effects 0.000 abstract description 8
239000000758 substrate Substances 0.000 abstract description 2
230000004481 post-translational protein modification Effects 0.000 abstract 2
210000004027 cell Anatomy 0.000 description 203
108020004414 DNA Proteins 0.000 description 173
108091032973 (ribonucleotides)n+m Proteins 0.000 description 117
239000013615 primer Substances 0.000 description 111
239000000047 product Substances 0.000 description 101
101150066555 lacZ gene Proteins 0.000 description 78
230000000694 effects Effects 0.000 description 57
238000003757 reverse transcription PCR Methods 0.000 description 55
230000008439 repair process Effects 0.000 description 52
208000022361 Human papillomavirus infectious disease Diseases 0.000 description 51
108091034117 Oligonucleotide Proteins 0.000 description 51
239000013612 plasmid Substances 0.000 description 50
238000003556 assay Methods 0.000 description 47
241000282414 Homo sapiens Species 0.000 description 38
206010028980 Neoplasm Diseases 0.000 description 38
108091028043 Nucleic acid sequence Proteins 0.000 description 34
108700024394 Exon Proteins 0.000 description 32
108010054218 Factor VIII Proteins 0.000 description 32
229960000301 factor viii Drugs 0.000 description 30
102000001690 Factor VIII Human genes 0.000 description 29
239000012634 fragment Substances 0.000 description 29
238000001890 transfection Methods 0.000 description 29
241000196324 Embryophyta Species 0.000 description 28
201000003883 Cystic fibrosis Diseases 0.000 description 26
239000003795 chemical substances by application Substances 0.000 description 25
108020004705 Codon Proteins 0.000 description 24
230000035772 mutation Effects 0.000 description 24
230000006870 function Effects 0.000 description 23
241000341655 Human papillomavirus type 16 Species 0.000 description 22
108020004635 Complementary DNA Proteins 0.000 description 20
238000010804 cDNA synthesis Methods 0.000 description 20
239000002299 complementary DNA Substances 0.000 description 20
238000010586 diagram Methods 0.000 description 20
108020001507 fusion proteins Proteins 0.000 description 20
102000037865 fusion proteins Human genes 0.000 description 20
108700012359 toxins Proteins 0.000 description 20
238000000338 in vitro Methods 0.000 description 19
230000001965 increasing effect Effects 0.000 description 17
230000007246 mechanism Effects 0.000 description 17
238000012360 testing method Methods 0.000 description 17
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
238000002474 experimental method Methods 0.000 description 15
230000014616 translation Effects 0.000 description 15
101100004352 Escherichia coli lacZ gene Proteins 0.000 description 14
241000699666 Mus <mouse, genus> Species 0.000 description 14
230000002950 deficient Effects 0.000 description 14
230000008685 targeting Effects 0.000 description 14
210000001519 tissue Anatomy 0.000 description 14
238000013519 translation Methods 0.000 description 14
238000005516 engineering process Methods 0.000 description 13
239000000284 extract Substances 0.000 description 13
102000040650 (ribonucleotides)n+m Human genes 0.000 description 12
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 12
238000013518 transcription Methods 0.000 description 12
230000035897 transcription Effects 0.000 description 12
238000011144 upstream manufacturing Methods 0.000 description 12
108091026890 Coding region Proteins 0.000 description 11
230000000692 anti-sense effect Effects 0.000 description 11
230000006907 apoptotic process Effects 0.000 description 11
201000011510 cancer Diseases 0.000 description 11
239000013613 expression plasmid Substances 0.000 description 11
230000004048 modification Effects 0.000 description 11
238000012986 modification Methods 0.000 description 11
230000001105 regulatory effect Effects 0.000 description 11
238000011282 treatment Methods 0.000 description 11
108091035707 Consensus sequence Proteins 0.000 description 10
229930193140 Neomycin Natural products 0.000 description 10
238000004458 analytical method Methods 0.000 description 10
238000012761 co-transfection Methods 0.000 description 10
238000012937 correction Methods 0.000 description 10
201000010099 disease Diseases 0.000 description 10
229960004927 neomycin Drugs 0.000 description 10
230000002441 reversible effect Effects 0.000 description 10
238000003786 synthesis reaction Methods 0.000 description 10
108090000994 Catalytic RNA Proteins 0.000 description 9
102000053642 Catalytic RNA Human genes 0.000 description 9
102000015097 RNA Splicing Factors Human genes 0.000 description 9
108010039259 RNA Splicing Factors Proteins 0.000 description 9
239000011543 agarose gel Substances 0.000 description 9
239000003153 chemical reaction reagent Substances 0.000 description 9
238000010367 cloning Methods 0.000 description 9
238000012217 deletion Methods 0.000 description 9
230000037430 deletion Effects 0.000 description 9
238000009396 hybridization Methods 0.000 description 9
239000003550 marker Substances 0.000 description 9
108091092562 ribozyme Proteins 0.000 description 9
101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 8
208000026350 Inborn Genetic disease Diseases 0.000 description 8
238000012408 PCR amplification Methods 0.000 description 8
150000001413 amino acids Chemical class 0.000 description 8
239000000872 buffer Substances 0.000 description 8
238000004113 cell culture Methods 0.000 description 8
238000001476 gene delivery Methods 0.000 description 8
208000016361 genetic disease Diseases 0.000 description 8
239000000463 material Substances 0.000 description 8
230000008569 process Effects 0.000 description 8
102000016607 Diphtheria Toxin Human genes 0.000 description 7
108010053187 Diphtheria Toxin Proteins 0.000 description 7
102000004190 Enzymes Human genes 0.000 description 7
108090000790 Enzymes Proteins 0.000 description 7
208000009292 Hemophilia A Diseases 0.000 description 7
238000010240 RT-PCR analysis Methods 0.000 description 7
238000010276 construction Methods 0.000 description 7
230000009395 genetic defect Effects 0.000 description 7
230000036961 partial effect Effects 0.000 description 7
108091008146 restriction endonucleases Proteins 0.000 description 7
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
208000023275 Autoimmune disease Diseases 0.000 description 6
241000282465 Canis Species 0.000 description 6
102100026735 Coagulation factor VIII Human genes 0.000 description 6
241000702421 Dependoparvovirus Species 0.000 description 6
201000003542 Factor VIII deficiency Diseases 0.000 description 6
102000005720 Glutathione transferase Human genes 0.000 description 6
108010070675 Glutathione transferase Proteins 0.000 description 6
108091092195 Intron Proteins 0.000 description 6
241001465754 Metazoa Species 0.000 description 6
241000699660 Mus musculus Species 0.000 description 6
240000004808 Saccharomyces cerevisiae Species 0.000 description 6
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical group O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 6
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 6
230000001413 cellular effect Effects 0.000 description 6
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 6
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 6
238000003780 insertion Methods 0.000 description 6
230000037431 insertion Effects 0.000 description 6
238000011580 nude mouse model Methods 0.000 description 6
238000000746 purification Methods 0.000 description 6
241000894007 species Species 0.000 description 6
238000001262 western blot Methods 0.000 description 6
206010008342 Cervix carcinoma Diseases 0.000 description 5
102000053602 DNA Human genes 0.000 description 5
241000282412 Homo Species 0.000 description 5
108020004682 Single-Stranded DNA Proteins 0.000 description 5
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 5
230000003321 amplification Effects 0.000 description 5
230000033228 biological regulation Effects 0.000 description 5
230000000903 blocking effect Effects 0.000 description 5
230000030833 cell death Effects 0.000 description 5
201000010881 cervical cancer Diseases 0.000 description 5
230000003247 decreasing effect Effects 0.000 description 5
238000011161 development Methods 0.000 description 5
230000018109 developmental process Effects 0.000 description 5
208000035475 disorder Diseases 0.000 description 5
238000001962 electrophoresis Methods 0.000 description 5
238000004520 electroporation Methods 0.000 description 5
230000002255 enzymatic effect Effects 0.000 description 5
238000001415 gene therapy Methods 0.000 description 5
208000015181 infectious disease Diseases 0.000 description 5
239000007924 injection Substances 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000012528 membrane Substances 0.000 description 5
238000003199 nucleic acid amplification method Methods 0.000 description 5
239000008194 pharmaceutical composition Substances 0.000 description 5
239000002953 phosphate buffered saline Substances 0.000 description 5
230000008488 polyadenylation Effects 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
238000003753 real-time PCR Methods 0.000 description 5
238000012163 sequencing technique Methods 0.000 description 5
239000000243 solution Substances 0.000 description 5
238000010186 staining Methods 0.000 description 5
108010062540 Chorionic Gonadotropin Proteins 0.000 description 4
241000186216 Corynebacterium Species 0.000 description 4
206010058467 Lung neoplasm malignant Diseases 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
235000014676 Phragmites communis Nutrition 0.000 description 4
102000004598 Small Nuclear Ribonucleoproteins Human genes 0.000 description 4
108010003165 Small Nuclear Ribonucleoproteins Proteins 0.000 description 4
238000013459 approach Methods 0.000 description 4
230000008901 benefit Effects 0.000 description 4
239000003114 blood coagulation factor Substances 0.000 description 4
230000015556 catabolic process Effects 0.000 description 4
238000003776 cleavage reaction Methods 0.000 description 4
230000007812 deficiency Effects 0.000 description 4
238000006731 degradation reaction Methods 0.000 description 4
238000013461 design Methods 0.000 description 4
239000012091 fetal bovine serum Substances 0.000 description 4
230000002068 genetic effect Effects 0.000 description 4
210000002510 keratinocyte Anatomy 0.000 description 4
210000003292 kidney cell Anatomy 0.000 description 4
208000020816 lung neoplasm Diseases 0.000 description 4
238000013507 mapping Methods 0.000 description 4
230000010076 replication Effects 0.000 description 4
230000001177 retroviral effect Effects 0.000 description 4
238000010839 reverse transcription Methods 0.000 description 4
239000000523 sample Substances 0.000 description 4
230000007017 scission Effects 0.000 description 4
238000006467 substitution reaction Methods 0.000 description 4
230000002588 toxic effect Effects 0.000 description 4
238000012546 transfer Methods 0.000 description 4
210000004881 tumor cell Anatomy 0.000 description 4
108091093088 Amplicon Proteins 0.000 description 3
108091007065 BIRCs Proteins 0.000 description 3
102000015081 Blood Coagulation Factors Human genes 0.000 description 3
108010039209 Blood Coagulation Factors Proteins 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
241000701822 Bovine papillomavirus Species 0.000 description 3
239000002126 C01EB10 - Adenosine Substances 0.000 description 3
108700010070 Codon Usage Proteins 0.000 description 3
102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 description 3
108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
102000055031 Inhibitor of Apoptosis Proteins Human genes 0.000 description 3
108020004485 Nonsense Codon Proteins 0.000 description 3
208000009608 Papillomavirus Infections Diseases 0.000 description 3
108010029485 Protein Isoforms Proteins 0.000 description 3
102000001708 Protein Isoforms Human genes 0.000 description 3
238000011529 RT qPCR Methods 0.000 description 3
108020004511 Recombinant DNA Proteins 0.000 description 3
238000012300 Sequence Analysis Methods 0.000 description 3
108091081024 Start codon Proteins 0.000 description 3
210000001744 T-lymphocyte Anatomy 0.000 description 3
108020005202 Viral DNA Proteins 0.000 description 3
229960005305 adenosine Drugs 0.000 description 3
230000004075 alteration Effects 0.000 description 3
229940024606 amino acid Drugs 0.000 description 3
238000000137 annealing Methods 0.000 description 3
229960002685 biotin Drugs 0.000 description 3
235000020958 biotin Nutrition 0.000 description 3
239000011616 biotin Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
108010006025 bovine growth hormone Proteins 0.000 description 3
239000006227 byproduct Substances 0.000 description 3
210000004899 c-terminal region Anatomy 0.000 description 3
239000013592 cell lysate Substances 0.000 description 3
239000007795 chemical reaction product Substances 0.000 description 3
229940104302 cytosine Drugs 0.000 description 3
230000029087 digestion Effects 0.000 description 3
239000003814 drug Substances 0.000 description 3
210000002950 fibroblast Anatomy 0.000 description 3
239000000499 gel Substances 0.000 description 3
210000005260 human cell Anatomy 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
230000003834 intracellular effect Effects 0.000 description 3
201000005202 lung cancer Diseases 0.000 description 3
210000004940 nucleus Anatomy 0.000 description 3
238000004806 packaging method and process Methods 0.000 description 3
239000013600 plasmid vector Substances 0.000 description 3
239000002243 precursor Substances 0.000 description 3
238000012545 processing Methods 0.000 description 3
125000000714 pyrimidinyl group Chemical group 0.000 description 3
238000011002 quantification Methods 0.000 description 3
230000008707 rearrangement Effects 0.000 description 3
230000009467 reduction Effects 0.000 description 3
231100000331 toxic Toxicity 0.000 description 3
231100000419 toxicity Toxicity 0.000 description 3
230000001988 toxicity Effects 0.000 description 3
230000032258 transport Effects 0.000 description 3
230000001960 triggered effect Effects 0.000 description 3
229940035893 uracil Drugs 0.000 description 3
LTPSRQRIPCVMKQ-UHFFFAOYSA-N 2-amino-5-methylbenzenesulfonic acid Chemical compound CC1=CC=C(N)C(S(O)(=O)=O)=C1 LTPSRQRIPCVMKQ-UHFFFAOYSA-N 0.000 description 2
KUWPCJHYPSUOFW-YBXAARCKSA-N 2-nitrophenyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1[N+]([O-])=O KUWPCJHYPSUOFW-YBXAARCKSA-N 0.000 description 2
229920000936 Agarose Polymers 0.000 description 2
206010060999 Benign neoplasm Diseases 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
101150029409 CFTR gene Proteins 0.000 description 2
108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
208000035473 Communicable disease Diseases 0.000 description 2
101710173353 Cytotoxicity-associated immunodominant antigen Proteins 0.000 description 2
KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine group Chemical group N[C@H](CCCCN)C(=O)O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 2
230000004543 DNA replication Effects 0.000 description 2
230000004568 DNA-binding Effects 0.000 description 2
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 2
241000238631 Hexapoda Species 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
101710125507 Integrase/recombinase Proteins 0.000 description 2
241000701646 Kappapapillomavirus 2 Species 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
101710163270 Nuclease Proteins 0.000 description 2
108700026244 Open Reading Frames Proteins 0.000 description 2
238000009004 PCR Kit Methods 0.000 description 2
101150015250 PTM gene Proteins 0.000 description 2
101150051118 PTM1 gene Proteins 0.000 description 2
102100027370 Parathymosin Human genes 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
101710084578 Short neurotoxin 1 Proteins 0.000 description 2
102000006601 Thymidine Kinase Human genes 0.000 description 2
108020004440 Thymidine kinase Proteins 0.000 description 2
101710182532 Toxin a Proteins 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
241000251539 Vertebrata <Metazoa> Species 0.000 description 2
108010067390 Viral Proteins Proteins 0.000 description 2
208000036142 Viral infection Diseases 0.000 description 2
206010052428 Wound Diseases 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
230000003213 activating effect Effects 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
230000037429 base substitution Effects 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000007547 defect Effects 0.000 description 2
238000004925 denaturation Methods 0.000 description 2
230000036425 denaturation Effects 0.000 description 2
238000001514 detection method Methods 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
238000005538 encapsulation Methods 0.000 description 2
239000003623 enhancer Substances 0.000 description 2
230000004927 fusion Effects 0.000 description 2
238000001502 gel electrophoresis Methods 0.000 description 2
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
230000036541 health Effects 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
208000031169 hemorrhagic disease Diseases 0.000 description 2
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
102000057593 human F8 Human genes 0.000 description 2
229960000900 human factor viii Drugs 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
239000007943 implant Substances 0.000 description 2
239000012678 infectious agent Substances 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
230000010354 integration Effects 0.000 description 2
PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
238000011813 knockout mouse model Methods 0.000 description 2
239000002502 liposome Substances 0.000 description 2
210000004962 mammalian cell Anatomy 0.000 description 2
230000000873 masking effect Effects 0.000 description 2
239000003094 microcapsule Substances 0.000 description 2
239000011859 microparticle Substances 0.000 description 2
229910052754 neon Inorganic materials 0.000 description 2
GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 2
238000002515 oligonucleotide synthesis Methods 0.000 description 2
108091008819 oncoproteins Proteins 0.000 description 2
102000027450 oncoproteins Human genes 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
229920002704 polyhistidine Polymers 0.000 description 2
239000013641 positive control Substances 0.000 description 2
SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
230000002062 proliferating effect Effects 0.000 description 2
125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 2
230000010837 receptor-mediated endocytosis Effects 0.000 description 2
230000006798 recombination Effects 0.000 description 2
238000005215 recombination Methods 0.000 description 2
230000007115 recruitment Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
238000012552 review Methods 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
238000010008 shearing Methods 0.000 description 2
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
230000005030 transcription termination Effects 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
238000000539 two dimensional gel electrophoresis Methods 0.000 description 2
241000701161 unidentified adenovirus Species 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
101150084750 1 gene Proteins 0.000 description 1
108020005345 3' Untranslated Regions Proteins 0.000 description 1
239000013607 AAV vector Substances 0.000 description 1
101710115267 ATP synthase protein MI25 Proteins 0.000 description 1
101710159080 Aconitate hydratase A Proteins 0.000 description 1
101710159078 Aconitate hydratase B Proteins 0.000 description 1
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
229930024421 Adenine Natural products 0.000 description 1
108010024223 Adenine phosphoribosyltransferase Proteins 0.000 description 1
102100029457 Adenine phosphoribosyltransferase Human genes 0.000 description 1
108700028369 Alleles Proteins 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
108020005544 Antisense RNA Proteins 0.000 description 1
CELPEWWLSXMVPH-CIUDSAMLSA-N Asp-Asp-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC(O)=O CELPEWWLSXMVPH-CIUDSAMLSA-N 0.000 description 1
BJDHEININLSZOT-KKUMJFAQSA-N Asp-Tyr-Lys Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(O)=O BJDHEININLSZOT-KKUMJFAQSA-N 0.000 description 1
241000193830 Bacillus <bacterium> Species 0.000 description 1
108091032955 Bacterial small RNA Proteins 0.000 description 1
102000051819 Baculoviral IAP Repeat-Containing 3 Human genes 0.000 description 1
241000255789 Bombyx mori Species 0.000 description 1
241000244203 Caenorhabditis elegans Species 0.000 description 1
101100454314 Caenorhabditis elegans lact-2 gene Proteins 0.000 description 1
102000011727 Caspases Human genes 0.000 description 1
108010076667 Caspases Proteins 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
108010062745 Chloride Channels Proteins 0.000 description 1
102000011045 Chloride Channels Human genes 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
208000034656 Contusions Diseases 0.000 description 1
239000003155 DNA primer Substances 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
241000450599 DNA viruses Species 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
206010011953 Decreased activity Diseases 0.000 description 1
102000007260 Deoxyribonuclease I Human genes 0.000 description 1
108010008532 Deoxyribonuclease I Proteins 0.000 description 1
101000928792 Drosophila melanogaster Death-associated inhibitor of apoptosis 1 Proteins 0.000 description 1
102100024074 Dystrobrevin alpha Human genes 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
101001091269 Escherichia coli Hygromycin-B 4-O-kinase Proteins 0.000 description 1
101710082714 Exotoxin A Proteins 0.000 description 1
108091092566 Extrachromosomal DNA Proteins 0.000 description 1
108010020195 FLAG peptide Proteins 0.000 description 1
XZWYTXMRWQJBGX-VXBMVYAYSA-N FLAG peptide Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 XZWYTXMRWQJBGX-VXBMVYAYSA-N 0.000 description 1
101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 description 1
108700039691 Genetic Promoter Regions Proteins 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
101150105574 HCG gene Proteins 0.000 description 1
208000031220 Hemophilia Diseases 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
206010062767 Hypophysitis Diseases 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
238000012404 In vitro experiment Methods 0.000 description 1
208000006877 Insect Bites and Stings Diseases 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
241001492282 Lambdapapillomavirus 2 Species 0.000 description 1
108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
239000012097 Lipofectamine 2000 Substances 0.000 description 1
229910021380 Manganese Chloride Inorganic materials 0.000 description 1
GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
108090000157 Metallothionein Proteins 0.000 description 1
101100054858 Mus musculus Adam12 gene Proteins 0.000 description 1
206010028309 Muscle haemorrhage Diseases 0.000 description 1
FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 1
108091061960 Naked DNA Proteins 0.000 description 1
241000244206 Nematoda Species 0.000 description 1
206010029719 Nonspecific reaction Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
101100522111 Oryza sativa subsp. japonica PHT1-11 gene Proteins 0.000 description 1
238000002944 PCR assay Methods 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
108010002747 Pfu DNA polymerase Proteins 0.000 description 1
ZYFVNVRFVHJEIU-UHFFFAOYSA-N PicoGreen Chemical compound CN(C)CCCN(CCCN(C)C)C1=CC(=CC2=[N+](C3=CC=CC=C3S2)C)C2=CC=CC=C2N1C1=CC=CC=C1 ZYFVNVRFVHJEIU-UHFFFAOYSA-N 0.000 description 1
108700001094 Plant Genes Proteins 0.000 description 1
241000242594 Platyhelminthes Species 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
102220513293 Protein VAC14 homolog_G52E_mutation Human genes 0.000 description 1
102000009096 Proto-Oncogene Proteins c-myb Human genes 0.000 description 1
108010087776 Proto-Oncogene Proteins c-myb Proteins 0.000 description 1
102000044126 RNA-Binding Proteins Human genes 0.000 description 1
101710105008 RNA-binding protein Proteins 0.000 description 1
239000012979 RPMI medium Substances 0.000 description 1
101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
108700005075 Regulator Genes Proteins 0.000 description 1
108010039491 Ricin Proteins 0.000 description 1
241000714474 Rous sarcoma virus Species 0.000 description 1
108091081021 Sense strand Proteins 0.000 description 1
208000026552 Severe hemophilia A Diseases 0.000 description 1
208000019802 Sexually transmitted disease Diseases 0.000 description 1
108010079723 Shiga Toxin Proteins 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
102000009040 Sp Transcription Factors Human genes 0.000 description 1
108010049181 Sp Transcription Factors Proteins 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
101001091268 Streptomyces hygroscopicus Hygromycin-B 7''-O-kinase Proteins 0.000 description 1
241000223892 Tetrahymena Species 0.000 description 1
108700019146 Transgenes Proteins 0.000 description 1
241000223104 Trypanosoma Species 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
102000006986 U2 Small Nuclear Ribonucleoprotein Human genes 0.000 description 1
108010072724 U2 Small Nuclear Ribonucleoprotein Proteins 0.000 description 1
101150047749 VIII gene Proteins 0.000 description 1
108010059722 Viral Fusion Proteins Proteins 0.000 description 1
108020000999 Viral RNA Proteins 0.000 description 1
108010027570 Xanthine phosphoribosyltransferase Proteins 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
210000001015 abdomen Anatomy 0.000 description 1
230000001594 aberrant effect Effects 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000004913 activation Effects 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
238000000246 agarose gel electrophoresis Methods 0.000 description 1
210000001552 airway epithelial cell Anatomy 0.000 description 1
229940126575 aminoglycoside Drugs 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
238000004873 anchoring Methods 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000001399 anti-metabolic effect Effects 0.000 description 1
238000003782 apoptosis assay Methods 0.000 description 1
230000005739 apoptotic body formation Effects 0.000 description 1
238000003149 assay kit Methods 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000007998 bicine buffer Substances 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
238000001815 biotherapy Methods 0.000 description 1
208000034158 bleeding Diseases 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
230000008499 blood brain barrier function Effects 0.000 description 1
210000001218 blood-brain barrier Anatomy 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
HJMZMZRCABDKKV-UHFFFAOYSA-N carbonocyanidic acid Chemical compound OC(=O)C#N HJMZMZRCABDKKV-UHFFFAOYSA-N 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000004700 cellular uptake Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
230000010428 chromatin condensation Effects 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
238000012411 cloning technique Methods 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
230000005757 colony formation Effects 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
239000003184 complementary RNA Substances 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
229940109239 creatinine Drugs 0.000 description 1
239000003431 cross linking reagent Substances 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
SPTYHKZRPFATHJ-HYZXJONISA-N dT6 Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)CO)[C@@H](O)C1 SPTYHKZRPFATHJ-HYZXJONISA-N 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
108010091883 dendrotoxin A Proteins 0.000 description 1
239000005547 deoxyribonucleotide Substances 0.000 description 1
125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
OZRNSSUDZOLUSN-LBPRGKRZSA-N dihydrofolic acid Chemical compound N=1C=2C(=O)NC(N)=NC=2NCC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OZRNSSUDZOLUSN-LBPRGKRZSA-N 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
239000000539 dimer Substances 0.000 description 1
238000006471 dimerization reaction Methods 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
230000005014 ectopic expression Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
230000013020 embryo development Effects 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000005183 environmental health Effects 0.000 description 1
230000009088 enzymatic function Effects 0.000 description 1
230000000925 erythroid effect Effects 0.000 description 1
238000012869 ethanol precipitation Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000000835 fiber Substances 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
238000006062 fragmentation reaction Methods 0.000 description 1
230000005021 gait Effects 0.000 description 1
238000012239 gene modification Methods 0.000 description 1
102000034356 gene-regulatory proteins Human genes 0.000 description 1
108091006104 gene-regulatory proteins Proteins 0.000 description 1
230000005017 genetic modification Effects 0.000 description 1
235000013617 genetically modified food Nutrition 0.000 description 1
210000004602 germ cell Anatomy 0.000 description 1
102000018146 globin Human genes 0.000 description 1
108060003196 globin Proteins 0.000 description 1
229960003180 glutathione Drugs 0.000 description 1
210000002149 gonad Anatomy 0.000 description 1
238000005734 heterodimerization reaction Methods 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
239000012145 high-salt buffer Substances 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
230000009215 host defense mechanism Effects 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
238000003365 immunocytochemistry Methods 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000007901 in situ hybridization Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000003999 initiator Substances 0.000 description 1
230000000749 insecticidal effect Effects 0.000 description 1
239000000138 intercalating agent Substances 0.000 description 1
238000002955 isolation Methods 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
238000005304 joining Methods 0.000 description 1
230000009191 jumping Effects 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
239000003446 ligand Substances 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
238000001638 lipofection Methods 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000004777 loss-of-function mutation Effects 0.000 description 1
201000005296 lung carcinoma Diseases 0.000 description 1
208000037841 lung tumor Diseases 0.000 description 1
108010003700 lysyl aspartic acid Proteins 0.000 description 1
238000010841 mRNA extraction Methods 0.000 description 1
UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
235000011285 magnesium acetate Nutrition 0.000 description 1
239000011654 magnesium acetate Substances 0.000 description 1
229940069446 magnesium acetate Drugs 0.000 description 1
239000011565 manganese chloride Substances 0.000 description 1
235000002867 manganese chloride Nutrition 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000002609 medium Substances 0.000 description 1
102000006240 membrane receptors Human genes 0.000 description 1
230000029052 metamorphosis Effects 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
108091070501 miRNA Proteins 0.000 description 1
HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
-1 mieroparticles Substances 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
239000008267 milk Substances 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
108091005573 modified proteins Proteins 0.000 description 1
102000035118 modified proteins Human genes 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
239000003068 molecular probe Substances 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
230000004660 morphological change Effects 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
229960000951 mycophenolic acid Drugs 0.000 description 1
239000002105 nanoparticle Substances 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
108091027963 non-coding RNA Proteins 0.000 description 1
102000042567 non-coding RNA Human genes 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
230000006849 nucleocytoplasmic transport Effects 0.000 description 1
230000030648 nucleus localization Effects 0.000 description 1
239000003921 oil Substances 0.000 description 1
229940046166 oligodeoxynucleotide Drugs 0.000 description 1
238000005457 optimization Methods 0.000 description 1
208000003154 papilloma Diseases 0.000 description 1
230000002023 papillomaviral effect Effects 0.000 description 1
244000045947 parasite Species 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
150000004713 phosphodiesters Chemical class 0.000 description 1
LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
210000003635 pituitary gland Anatomy 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
210000003240 portal vein Anatomy 0.000 description 1
235000011056 potassium acetate Nutrition 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000002028 premature Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000005522 programmed cell death Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
238000002731 protein assay Methods 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
230000004853 protein function Effects 0.000 description 1
231100000654 protein toxin Toxicity 0.000 description 1
150000003212 purines Chemical group 0.000 description 1
230000005855 radiation Effects 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
238000012827 research and development Methods 0.000 description 1
230000008458 response to injury Effects 0.000 description 1
238000004366 reverse phase liquid chromatography Methods 0.000 description 1
239000003161 ribonuclease inhibitor Substances 0.000 description 1
239000002342 ribonucleoside Substances 0.000 description 1
238000012216 screening Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000004904 shortening Methods 0.000 description 1
238000010583 slow cooling Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
235000013599 spices Nutrition 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000000829 suppository Substances 0.000 description 1
229940113082 thymine Drugs 0.000 description 1
230000036962 time dependent Effects 0.000 description 1
238000004448 titration Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000563 toxic property Toxicity 0.000 description 1
230000007888 toxin activity Effects 0.000 description 1
239000012096 transfection reagent Substances 0.000 description 1
238000006276 transfer reaction Methods 0.000 description 1
238000011830 transgenic mouse model Methods 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000014621 translational initiation Effects 0.000 description 1
230000005945 translocation Effects 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
230000009385 viral infection Effects 0.000 description 1

Classifications

- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/52—Improvements relating to the production of bulk chemicals using catalysts, e.g. selective catalysts

Landscapes

Micro-Organisms Or Cultivation Processes Thereof (AREA)

CA002558640A 2001-01-08 2002-01-08 Procedes et compositions s'utilisant dans le trans-epissage d'arn induit par complexe d'epissage Abandoned CA2558640A1 (fr)

Applications Claiming Priority (11)

Application Number	Priority Date	Filing Date	Title
US09/756,096 US20030077754A1 (en)	1995-12-15	2001-01-08	Methods and compositions for use in spliceosome mediated RNA trans-splicing
US09/756,095 US20020115207A1 (en)	1995-12-15	2001-01-08	Methods and compositions for use in spliceosome mediated RNA trans-splicing
US09/756,096		2001-01-08
US09/756,095		2001-01-08
US09/756,097 US20060088938A1 (en)	1995-12-15	2001-01-08	Methods and compositions for use in spliceosome mediated RNA trans-splicing in plants
US09/756,097		2001-01-08
US09/838,858 US20030148937A1 (en)	1995-12-15	2001-04-20	Methods and compositions for use in spliceosome mediated RNA trans-splicing
US09/838,858		2001-04-20
US09/941,492		2001-08-29
US09/941,492 US20030027250A1 (en)	1995-12-15	2001-08-29	Methods and compositions for use in spliceosome mediated RNA trans-splicing
CA002434118A CA2434118A1 (fr)	2001-01-08	2002-01-08	Procedes et compositions s'utilisant dans le trans-epissage d'arn induit par complexe d'epissage

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002434118A Division CA2434118A1 (fr)	2001-01-08	2002-01-08	Procedes et compositions s'utilisant dans le trans-epissage d'arn induit par complexe d'epissage

Publications (1)

Publication Number	Publication Date
CA2558640A1 true CA2558640A1 (fr)	2002-07-11

Family

ID=37114262

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002558640A Abandoned CA2558640A1 (fr)	2001-01-08	2002-01-08	Procedes et compositions s'utilisant dans le trans-epissage d'arn induit par complexe d'epissage

Country Status (1)

Country	Link
CA (1)	CA2558640A1 (fr)

2002
- 2002-01-08 CA CA002558640A patent/CA2558640A1/fr not_active Abandoned

Publication	Publication Date	Title
US6280978B1 (en)	2001-08-28	Methods and compositions for use in spliceosome mediated RNA trans-splicing
US6083702A (en)	2000-07-04	Methods and compositions for use in spliceosome mediated RNA trans-splicing
JP4321877B2 (ja)	2009-08-26	トランス―スプライスにより生成される治療用分子
US20060246422A1 (en)	2006-11-02	Methods and compositions for use in spliceosome mediated RNA trans-splicing
US20110003883A1 (en)	2011-01-06	Allosteric trans-splicing group i ribozyme whose activity of target-specific rna replacement is controlled by theophylline
AU2002246959B2 (en)	2008-03-06	Spliceosome mediated RNA trans-splicing
AU2002246959A1 (en)	2003-01-23	Spliceosome mediated RNA trans-splicing
EP1521766B1 (fr)	2012-11-07	Trans-epissage d'arn a mediation par spliceosome (technique smart) et correction de defauts genetiques de facteur viii a l'aide du trans-epissage d'arn a mediation par spliceosome
US20030077754A1 (en)	2003-04-24	Methods and compositions for use in spliceosome mediated RNA trans-splicing
US20030148937A1 (en)	2003-08-07	Methods and compositions for use in spliceosome mediated RNA trans-splicing
US20020115207A1 (en)	2002-08-22	Methods and compositions for use in spliceosome mediated RNA trans-splicing
AU2003213270A1 (en)	2003-09-09	Trans-splicing mediated imaging of gene expression
AU2004237884B2 (en)	2008-09-18	Spliceosome mediated RNA trans-splicing
CA2558640A1 (fr)	2002-07-11	Procedes et compositions s'utilisant dans le trans-epissage d'arn induit par complexe d'epissage
AU2003215249B2 (en)	2008-07-03	Methods and compositions for use in spliceosome mediated RNA trans-splicing
US20060088938A1 (en)	2006-04-27	Methods and compositions for use in spliceosome mediated RNA trans-splicing in plants
AU2004237883A1 (en)	2005-01-06	Spliceosome mediated RNA trans-splicing
US20020193580A1 (en)	2002-12-19	Methods and compositions for use in spliceosome mediated RNA trans-splicing
JP2009000120A (ja)	2009-01-08	スプライソソーム媒介ｒｎａトランス−スプライシングにおける使用のための方法及び組成物
KR20250158036A (ko)	2025-11-05	리보자임-매개 rna 조립 및 발현
US20030153054A1 (en)	2003-08-14	Methods and compositions for use in spliceosome mediated RNA trans-splicing

Legal Events

Date	Code	Title	Description
2007-12-13	EEER	Examination request
2012-09-21	FZDE	Dead
2012-12-16	FZDE	Dead	Effective date: 20120921